Mather, Kieren J.

Quantitative Insulin Sensitivity Check Index: A Simple, Accurate Method for Assessing Insulin Sensitivity In Humans

Katz, A., Nambi, S. S., Mather, K., Baron, A. D., Follmann, D. A., Sullivan, G., & Quon, M. J. (2000) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 3,931

Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study

Perreault, L., Pan, Q., Mather, K. J., Watson, K. E., Hamman, R. F., & Kahn, S. E. (2012) · The Lancet

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 532

Improved Endothelial Function With Metformin in Type 2 Diabetes Mellitus

Mather, K. J., Verma, S., & Anderson, T. J. (2001) · Journal of the American College of Cardiology

Nitric Oxide and Endothelin EffectsDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 513

Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity

Wharton, S., Blevins, T., Connery, L., Rosenstock, J., Raha, S., Liu, R., Ma, X., Mather, K. J., Haupt, A., Robins, D., et al. (2023) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 478

β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment

Halban, P. A., Polonsky, K. S., Bowden, D. W., Hawkins, M. A., Ling, C., Mather, K. J., Powers, A. C., Rhodes, C. J., Sussel, L., & Weir, G. C. (2014) · Diabetes Care

Pancreatic function and diabetesDiabetes Treatment and Management

Cited by 460

Repeatability Characteristics of Simple Indices of Insulin Resistance: Implications for Research Applications

Mather, K. J., Hunt, A. E., Steinberg, H. O., Paradisi, G., Hook, G., Katz, A., Quon, M. J., & Baron, A. D. (2001) · The Journal of Clinical Endocrinology & Metabolism

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 363

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Sanyal, A. J., Kaplan, L. M., Frias, J. P., Brouwers, B., Wu, Q., Thomas, M. K., Harris, C., Schloot, N. C., Du, Y., Mather, K. J., et al. (2024) · Nature Medicine

Liver Disease Diagnosis and TreatmentPharmacology and Obesity Treatment

Cited by 315

Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel-arm, phase 1 clinical trial

Heise, T., Mari, A., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Coskun, T., Thomas, M. K., Mather, K. J., Haupt, A., et al. (2022) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 268

Long‐term effects of the Diabetes Prevention Program interventions on cardiovascular risk factors: a report from the DPP Outcomes Study

The Diabetes Prevention Program Outcomes Study Research Group; prepared on behalf of the DPPOS Research Group, Orchard, T. J., Temprosa, M., Barrett‐Connor, E., Fowler, S. E., Goldberg, R. B., Mather, K. J., Marcovina, S. M., Montez, M., Ratner, R. E., et al. (2013) · Diabetic Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 214

Tirzepatide Reduces Appetite, Energy Intake, and Fat Mass in People With Type 2 Diabetes

Heise, T., DeVries, J. H., Urva, S., Li, J., Pratt, E. J., Thomas, M. K., Mather, K. J., Karanikas, C. A., Dunn, J., Haupt, A., et al. (2023) · Diabetes Care

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 208

Efficacy and safety of oral orforglipron in patients with type 2 diabetes: A multicentre, randomised, dose-response, phase 2 study

Frias, J. P., Hsia, S., Eyde, S., Liu, R., Ma, X., Konig, M., Kazda, C., Mather, K. J., Haupt, A., Pratt, E., et al. (2023) · The Lancet

Diabetes Treatment and ManagementPharmacology and Obesity Treatment

Cited by 184

Impact of insulin and metformin versus metformin alone on β-cell function in youth with impaired glucose tolerance or recently diagnosed type 2 diabetes

The RISE Consortium, Nadeau, K. J., Hannon, T. S., Edelstein, S. L., Arslanian, S. A., Caprio, S., Leschek, E. W., Zeitler, P. S., Buchanan, T. A., Ehrmann, D. A., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 176

Statin use and risk of developing diabetes: results from the Diabetes Prevention Program

Crandall, J. P., Mather, K., Rajpathak, S. N., Goldberg, R. B., Watson, K., Foo, S., Ratner, R., Barrett-Connor, E., & Temprosa, M. (2017) · BMJ Open Diabetes Research & Care

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 137

Regression From Prediabetes to Normal Glucose Regulation Is Associated With Reduction in Cardiovascular Risk: Results From the Diabetes Prevention Program Outcomes Study

Perreault, L., Temprosa, M., Mather, K. J., Horton, E., Kitabchi, A., Larkin, M., Montez, M. G., Thayer, D., Orchard, T. J., Hamman, R. F., et al. (2014) · Diabetes Care

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 131

Long-term effects of metformin on diabetes prevention: identification of subgroups that benefited most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study

Diabetes Prevention Program Research Group, Nathan, D. M., Knowler, W. C., Edelstein, S., Crandall, J. P., Dabelea, D., Goldberg, R. B., Kahn, S. E., Mather, K. J., Trandafirescu, G., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 128

Insulin resistance in the vasculature

Mather, K. J., Steinberg, H. O., & Baron, A. D. (2013) · Journal of Clinical Investigation

Diabetes, Cardiovascular Risks, and LipoproteinsNitric Oxide and Endothelin Effects

Cited by 120

Discovery, development, and clinical proof of mechanism of LY3463251, a long-acting GDF15 receptor agonist

Benichou, O., Coskun, T., Gonciarz, M. D., Garhyan, P., Adams, A. C., Du, Y., Dunbar, J. D., Martin, J. A., Mather, K. J., Pickard, R. T., et al. (2023) · Cell Metabolism

Regulation of Appetite and ObesityGDF15 and Related Biomarkers

Cited by 115

A Prospective Study to Establish a New-Onset Diabetes Cohort: From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Maitra, A., Sharma, A., Brand, R. E., Van Den Eeden, S. K., Fisher, W. E., Hart, P. A., Hughes, S. J., Mather, K. J., Pandol, S. J., Park, W. G., et al. (2018) · Pancreas

Pancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment

Cited by 93

Does diabetes prevention translate into reduced long-term vascular complications of diabetes?

and the DPP Research Group, Nathan, D. M., Bennett, P. H., Crandall, J. P., Edelstein, S. L., Goldberg, R. B., Kahn, S. E., Knowler, W. C., Mather, K. J., Mudaliar, S., et al. (2019) · Diabetologia

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 91

Lack of durable improvements in β-cell function following withdrawal of pharmacological interventions in adults with impaired glucose tolerance or recently diagnosed type 2 diabetes

The RISE Consortium, Ehrmann, D. A., Temple, K. A., Rue, A., Barengolts, E., Mokhlesi, B., Van Cauter, E., Sam, S., Miller, M. A., Kahn, S. E., et al. (2019) · Diabetes Care

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 73

The impact of physical activity on the prevention of type 2 diabetes: Evidence and lessons learned from the Diabetes Prevention Program, a long-standing clinical trial incorporating subjective and objective activity measures

Kriska, A. M., Rockette-Wagner, B., Edelstein, S. L., Bray, G. A., Delahanty, L. M., Hoskin, M. A., Horton, E. S., Venditti, E. M., Knowler, W. C., DPP Research Group, et al. (2021) · Diabetes Care

Physical Activity and HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 70

Program ACTIVE II: Outcomes from a randomized, multistate community-based depression treatment for rural and urban adults with type 2 diabetes

de Groot, M., Shubrook, J. H., Hornsby, W. G., Pillay, Y., Mather, K. J., Fitzpatrick, K., Yang, Z., & Saha, C. (2019) · Diabetes Care

Diabetes Management and EducationPhysical Activity and Health

Cited by 56

Exploring residual risk for diabetes and microvascular disease in the Diabetes Prevention Program Outcomes Study (DPPOS)

Perreault, L., Pan, Q., Aroda, V. R., Barrett-Connor, E., Dabelea, D., Dagogo-Jack, S., Hamman, R. F., Kahn, S. E., Mather, K. J., Knowler, W. C., et al. (2017) · Diabetic Medicine

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Management and Research

Cited by 55

Evaluation of a Mixed Meal Test for Diagnosis and Characterization of PancrEaTogEniC DiabeTes Secondary to Pancreatic Cancer and Chronic Pancreatitis: Rationale and Methodology for the DETECT Study From the Consortium for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

Hart, P. A., Andersen, D. K., Mather, K. J., Castonguay, A. C., Bajaj, M., Bellin, M. D., Bradley, D., Contreras, N., Habtezion, A., Korc, M., et al. (2018) · Pancreas

Pancreatitis Pathology and TreatmentPancreatic function and diabetes

Cited by 46